VNDA Insider Trading
Insider Ownership Percentage: 10.00%
Insider Buying (Last 12 Months): $279,580.00
Insider Selling (Last 12 Months): $39,175.92
Vanda Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Vanda Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Vanda Pharmaceuticals Share Price & Price History
Current Price: $4.39
Price Change: +0.30 (1.20%)
As of 05/30/2025 05:00 PM ET
Vanda Pharmaceuticals Insider Trading History
SEC Filings (Institutional Ownership Changes) for Vanda Pharmaceuticals (NASDAQ:VNDA)
88.14% of Vanda Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
Institutional Buying and Selling by Quarter
This chart shows the instiutional buying and selling at VNDA by year and by quarter.
Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
Vanda Pharmaceuticals Institutional Trading History
Data available starting January 2016
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Read More on Vanda Pharmaceuticals
Volume
234,824 shs
Average Volume
706,210 shs
Market Capitalization
$258.72 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.69
Who are the company insiders with the largest holdings of Vanda Pharmaceuticals?
Who are the major institutional investors of Vanda Pharmaceuticals?
Which major investors are selling Vanda Pharmaceuticals stock?
Within the previous quarter, VNDA stock was sold by these institutional investors:
- Jacobs Levy Equity Management Inc.
- Goldman Sachs Group Inc.
- Wellington Management Group LLP
- Charles Schwab Investment Management Inc.
- Monaco Asset Management SAM
- Martingale Asset Management L P
- Trexquant Investment LP
- Invesco Ltd.
During the previous year, company insiders that have sold Vanda Pharmaceuticals company stock include:
- Mihael Hristos Polymeropoulos (CEO)
- Kevin Patrick Moran (CFO)
Learn More investors selling Vanda Pharmaceuticals stock.
Which major investors are buying Vanda Pharmaceuticals stock?
Within the last quarter, VNDA stock was purchased by institutional investors including:
- Millennium Management LLC
- Nuveen LLC
- Caption Management LLC
- Universal Beteiligungs und Servicegesellschaft mbH
- GSA Capital Partners LLP
- Connor Clark & Lunn Investment Management Ltd.
- XTX Topco Ltd
- Walleye Capital LLC
In the last year, these company insiders have bought Vanda Pharmaceuticals stock:
- Mihael Hristos Polymeropoulos (CEO)
- Kevin Patrick Moran (CFO)
Learn More investors buying Vanda Pharmaceuticals stock.